Montelukast Kern Pharma (Montelukast Sodium)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from binding. This inhibition stops the cascade that leads to bronchoconstriction, mucus production, and inflammation, thereby improving airway patency and reducing allergic symptoms.

The specific dose of Montelukast Kern Pharma is determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. Healthcare providers follow approved dosing guidelines and adjust as needed for optimal control.

Safety data for Montelukast in pregnancy and lactation are limited. Prescribers should weigh potential benefits against possible risks and consider alternative therapies when appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who need additional control beyond inhaled therapy, though it does not replace rescue bronchodilators.

Montelukast Kern Pharma should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Montelukast Kern Pharma is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks, though rare, include neuropsychiatric events such as depression or suicidal thoughts, severe allergic reactions like angioedema, and rare skin conditions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast Kern Pharma is contraindicated in individuals with known hypersensitivity to montelukast sodium or any of its excipients. It should also be used with caution in patients with severe hepatic impairment or those who have experienced serious neuropsychiatric reactions to the drug.